|
Real-time Estimate
Cboe BZX
07:55:04 07/11/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 6.960 USD | +4.98% |
|
-2.51% | -61.51% |
| 12:15am | BofA Securities Adjusts Avalo Therapeutics Price target to $24 From $29 | MT |
| 06/11 | Wedbush Adjusts Price Target on Avalo Therapeutics to $20 From $22, Keeps Outperform Rating | MT |
Company Valuation: Avalo Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 190.9 | 47.45 | 7.295 | 77.74 | 329.3 | 355.6 | - | - |
| Change | - | -75.15% | -84.63% | 965.79% | 323.58% | 7.97% | - | - |
| Enterprise Value (EV) 1 | 190.9 | 47.45 | 7.295 | 77.74 | 231 | -68.43 | 50.02 | -71.23 |
| Change | - | -75.15% | -84.63% | 965.79% | 197.1% | -129.63% | 173.09% | -242.42% |
| P/E | -2.05x | -1.14x | -0.08x | -0.94x | -3.11x | -2.34x | -2.37x | -2.47x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0.1x | 0x | 2.28x | 0.59x |
| Capitalization / Revenue | 35.4x | 2.63x | 3.79x | 176x | 5,582x | - | - | - |
| EV / Revenue | 35.4x | 2.63x | 3.79x | 176x | 3,915x | - | - | - |
| EV / EBITDA | - | - | - | - | - | 0.71x | -0.38x | - |
| EV / EBIT | -2.32x | -1.27x | -0.27x | -1.13x | -3.17x | 0.63x | -0.36x | 0.47x |
| EV / FCF | -2.69x | -1.77x | - | -1.58x | -4.49x | 0.83x | -0.44x | 0.52x |
| FCF Yield | -37.2% | -56.6% | - | -63.1% | -22.3% | 120% | -226% | 194% |
| Dividend per Share 2 | - | - | - | - | - | 0.0114 | 0.00075 | - |
| Rate of return | - | - | - | - | - | 0.17% | 0.01% | - |
| EPS 2 | -2,390 | -1,063 | -114 | -7.94 | -5.84 | -2.831 | -2.802 | -2.683 |
| Distribution rate | - | - | - | - | - | -0.4% | -0.03% | - |
| Net sales 1 | 5.398 | 18.05 | 1.924 | 0.441 | 0.059 | - | - | - |
| EBITDA 1 | - | - | - | - | - | -96.92 | -132.7 | - |
| EBIT 1 | -82.13 | -37.44 | -27.35 | -68.51 | -72.92 | -108.8 | -140.1 | -151.3 |
| Net income 1 | -84.38 | -41.66 | -31.54 | -35.13 | -78.26 | -111.4 | -138.5 | -163.7 |
| Net Debt 1 | - | - | - | - | -98.34 | -424 | -305.6 | -426.8 |
| Reference price 2 | 4,895.962 | 1,209.614 | 9.100 | 7.430 | 18.160 | 6.630 | 6.630 | 6.630 |
| Nbr of stocks (in thousands) | 39 | 39.2 | 802 | 10,464 | 18,134 | 53,630 | - | - |
| Announcement Date | 2/3/22 | 29/3/23 | 29/3/24 | 20/3/25 | 23/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.34x | - | 0.71x | - | 356M | |
| 18.32x | 6.97x | 13.35x | 1.63% | 69.4B | |
| 30.72x | 8.25x | 27.72x | 0.05% | 57.24B | |
| 39.18x | 6.93x | 20.69x | 0.83% | 57.62B | |
| 34.57x | 3.29x | 14.19x | -.--% | 43.65B | |
| 51.08x | 5.91x | 32.37x | -.--% | 44.03B | |
| -18.44x | 177.78x | -19.56x | -.--% | 38.08B | |
| 36.57x | 9x | 23.45x | 0.36% | 36.31B | |
| 44.16x | 7.87x | 26.34x | -.--% | 32.61B | |
| 29.41x | 6.22x | 16.14x | -.--% | 25.47B | |
| Average | 26.32x | 25.80x | 15.54x | 0.32% | 40.48B | |
| Weighted average by Cap. | 29.30x | 22.92x | 17.61x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AVTX Stock
- Valuation Avalo Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
